A new treatment for TTP?

@article{Fakhouri2006ANT,
  title={A new treatment for TTP?},
  author={Fadi Fakhouri and Benjamin Deroure and Aur{\'e}lie Hummel},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2006},
  volume={21 3},
  pages={
          577-9
        }
}
  • F. Fakhouri, Benjamin Deroure, A. Hummel
  • Published 1 March 2006
  • Biology
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Nephrol Dial Transplant 2006; 21: 577–579 The authors would like to add the following to their article. The data discussed in this editorial are from a multicentric trial with the following participants: F. Fakhouri, B. Deroure, P. Lesavre, J.-P. Grünfeld (Necker, Paris), A. Veyradier, M. Wolf (Antoine Béclère, Clamart), G. Remuzzi (Mario Negri Institute, Bergamo, Italy), Jean-Paul Vernant (Pitié-Salpêtrière, Paris), G. Kaplanski, P. Poullin (La Conception, Marseille), R. Binaut, P. Vanhile… 
View on PubMed
academic.oup.com
4 Citations

Figures from this paper

4 Citations

Citation Type

Citation Type

Rituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literature
TLDR
It is concluded that rituximab is an useful addition to plasma exchange treatment in TTP, but its exact role and dosing need to be verified in prospective studies.
Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura
TLDR
Two patients with chronic relapsing TTP who were treated successfully with rituximab are reported here, however, both experienced TTP relapse following sustained and prolonged remissions for 21 and 37 months, respectively.
The safety of oral use of L-glutamine in middle-aged and elderly individuals.
Changing the terminology from kidney replacement therapy to kidney support therapy
  • R. Raina, Hirva Joshi, R. Chakraborty
  • Medicine, Biology
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2020
TLDR
The use of various modes of kidney replacement therapy in treating renal and nonrenal complications are discussed to illustrate why kidney support therapy is a more appropriate terminology than kidney replacement Therapy.

References

SHOWING 1-10 OF 15 REFERENCES
Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature
TLDR
A patient with relapsing TTP because of ADAMTS13 inhibitors is described, who failed to achieve sustained remission despite therapies with plasma exchange, steroids, vincristine, staphylococcal protein A and splenectomy, and experience suggests that rituximab therapy deserves further investigation.
Management Of Thrombotic Thrombocytopenic Purpura
TLDR
It is proposed that TTP should be redefined as a syndrome of Coomb's negative microangiopathic haemolytic anaemia and thrombocytopenia in the absence of other possible causes of these manifestations.
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
TLDR
The finding of the clinical efficacy of selective B cell blockade indicates that B cells play a critical role in rheumatoid synovitis, at least in a subset of patients.
An open study of B lymphocyte depletion in systemic lupus erythematosus.
TLDR
This study provides sufficient evidence for the safety and possible efficacy of B lymphocyte depletion therapy in SLE to justify a formal controlled trial.
Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
  • H. Tsai
  • Biology, Medicine
    Journal of the American Society of Nephrology : JASN
  • 2003
TLDR
Assay of ADAMTS13 activity distinguishes TTP from HUS and other types of thrombotic microangiopathy (TMA); therefore, the term TTP/HUS should be avoided because it obscures the known or potential differences among the various types of TMA.
Splenectomy Done during Hematologic Remission To Prevent Relapse in Patients with Thrombotic Thrombocytopenic Purpura
TLDR
The use of splenectomy is described in six patients who had had relapse of thrombotic throm bocytopenic purpura and how this therapy was tapered and discontinued within 2 months of achievement of remission is described.
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
TLDR
Rituximab is now also approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone).
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
TLDR
Assays of ADAMTS13 activity and inhibitors in addition to the clinical categories (idiopathic TTP and nonidiopathy TTP) are predictive of outcome and may be useful to tailor patient treatment.
Ten years of prophylactic treatment with fresh‐frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor‐cleaving protease
We report the results of 10 years of prophylactic fresh‐frozen plasma (FFP) infusion therapy in a 14‐year‐old girl with chronic relapsing thrombotic thrombocytopenic purpura (TTP), in whom a severe…
Recent advances in thrombotic thrombocytopenic purpura.
TLDR
Recent advances in assay methods that should facilitate routine laboratory testing of ADAMTS13 for patients with thrombotic microangiopathy are described, and the role of ADamTS13 testing in choosing therapy remains uncertain.
...
1
2
...